AKB-5169

On Monday, Akebia Therapeutics Inc (NASDAQ: AKBA) signed a $1 million research and license agreement with Johnson & Johnson (NYSE: JNJ) to access hundreds of hypoxia inducible factor (HIF)-targeted compounds. This access includes a coveted preclinical candidate for inflammatory bowel disease (...